ArticleBiomarker research2026
Intra-aortic balloon pump use and in-hospital mortality in acute myocardial infarction with Killip class III or IV: a nationwide cohort study.
Article in Biomarker research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThe intra-aortic balloon pump (IABP) remains widely used in acute myocardial infarction (AMI) complicated by severe heart failure or shock, particularly where access to advanced mechanical circulatory support is limited. Contemporary nationwide evidence in AMI presenting with Killip class III or IV is scarce. We therefore evaluated IABP use during hospitalization and in-hospital outcomes in this setting.
methodsWe did a nationwide cohort study using the China Chest Pain Center Database (4089 hospitals; 2019 to 2023). Adults aged ≥ 18 years with AMI and Killip class III or IV who underwent percutaneous coronary intervention (PCI) were included. The exposure was IABP use during hospitalization versus no recorded mechanical circulatory support; the primary outcome was in-hospital all-cause mortality. Associations were estimated by stabilized inverse probability of treatment weighting based on Bayesian additive regression trees (sIPTW-BART) and weighted Cox models, supported by prespecified sensitivity analyses.
resultsAmong 37 477 patients, 6051 received IABP. In the sIPTW-BART-weighted cohort, IABP use was associated with higher in-hospital all-cause mortality (28.1% vs. 19.1%; hazard ratio [HR] 1.48, 95% CI 1.37-1.61) and cardiovascular mortality (27.5% vs. 18.8%; HR 1.48, 1.36-1.61), and recorded in-hospital complications differed between groups. Findings were consistent across prespecified sensitivity analyses. The E-value for the lower confidence limit was 2.08, indicating the minimum strength of unmeasured confounding required to explain away the primary association.
conclusionsAmong patients undergoing PCI for AMI with Killip class III or IV presentation, IABP use during hospitalization was associated with higher in-hospital all-cause and cardiovascular mortality. These findings suggest potential risk associated with routine IABP use in this population and support further prospective studies to identify patients most likely to benefit or be harmed. Residual confounding by indication cannot be excluded; these findings should therefore be interpreted as associations rather than as causal effects of IABP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.